{"schema_version":"secwatch.filing_event.v1","accession":"0001326190-24-000046","form_type":"8-K","ticker":"ALT","cik":"0001326190","company_name":"Altimmune, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.115648+00:00","generated_at":"2026-05-30T01:38:02.568021+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Altimmune names Greg Weaver CFO, with $475k salary and 225k option grant","bullets":["Mr. Weaver appointed CFO effective Nov 11, 2024; previously CFO at atai Life Sciences.","Employment terms: annual salary $475k, target bonus 40%, sign-on option for 225k shares and 75k RSUs.","Andrew Shutterly transitions from Interim CFO to Corporate Controller.","Weaver led $225M IPO at atai Life Sciences and has 25+ years of biotech finance experience."],"urls":{"canonical":"https://secwatch.observer/filing/0001326190-24-000046","json":"https://secwatch.observer/filing/0001326190-24-000046.json","markdown":"https://secwatch.observer/filing/0001326190-24-000046.md","text":"https://secwatch.observer/filing/0001326190-24-000046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326190/000132619024000046/0001326190-24-000046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326190/000132619024000046/alt-20241111x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:38:02.568021+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5848b34d70","claim":"Gregory Weaver was appointed as Chief Financial Officer at Altimmune, Inc..","evidence_excerpt":"On November 11, 2024, Altimmune, Inc. (the “Company”) issued a press release announcing the decision of the Company’s Board of Directors (the “Board”) to appoint Mr. Gregory Weaver as the Company’s Chief Financial Officer (“CFO”), effective November 11, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326190/000132619024000046/0001326190-24-000046-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}